IM Cannabis Corp. (IMCC): Financial results for Q2 2026
IM Cannabis Corp. (IMCC) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results TORONTO and GLIL YAM, Israel, August 13, 2026 /PRNewswire/ -- IM Cannabis Corp. (" IMC " or the " Company ") (Nasdaq: IMCC), today announced its financial results for the three and six m
How this was made
The 30-second read
Why it matters
The earnings miss underscores cash‑flow challenges for small‑cap cannabis firms and could trigger sector rotation.
Market read
Earnings decline highlights sector‑wide pressures; traders may adjust exposure to cannabis equities.
What to watch
Potential pipeline expansion in Germany and upcoming regulatory changes are not reflected in Q2 results.
Background
IM Cannabis Corp. is a Nasdaq‑listed medical cannabis company operating retail and distribution platforms in Israel and Germany.
Ticker impact
IM Cannabis Corp. reported Q2 2026 revenue of $16.3 million, a 35% YoY decline, and a net loss of $6.9 million.
Stock may slide 5‑10% as investors reassess valuation.
Losses and cash burn suggest near‑term pressure, but low float could limit move magnitude.
Market effects
Weak earnings may weigh on the broader Canadian and Israeli medical cannabis sector.
Negative sentiment could spread to Israeli and German markets where IMC operates.
Limited to niche cannabis investors; minimal broader market effect.
Counterpoint
Low valuation and cash position may attract value‑focused buyers despite near‑term weakness.
Key entities
- CompanyIM Cannabis Corp.
Nasdaq‑listed medical cannabis producer focused on Israel and Germany markets.




